Radiomics Based on DCE-MRI for Predicting Response to Neoadjuvant Therapy in Breast Cancer

Delta-Radiomics Based on Dynamic Contrast-Enhanced MRI for Predicting Lymphovascular Invasion in Invasive Breast Cancer

RATIONALE AND OBJECTIVES

Treatment strategies for invasive breast cancer require accurate lymphovascular invasion (LVI) predictions. This study aimed to investigate the effectiveness of delta radiomics based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for assessing LVI and develop a nomogram to aid treatment decisions.

MATERIALS AND METHODS

Overall, 293 patients with resectable invasive breast cancer underwent preoperative DCE-MRI. Radiomic features were extracted from pre-contrast (A0), first post-contrast (A1), and subtracted images of A0 and A1. Three radiomics models were developed using several data analyses; logistic analyses were performed to identify radiological features to predict the LVI status. A hybrid model integrating both radiological features and optimal radiomics was developed. Receiver operating characteristic analysis was employed to evaluate model performance, using the area under the curve (AUC) as a quantitative metric for discriminative ability.

RESULTS

In the test set, the Radiomics-Delta model, with 17 radiomic features, had an AUC of 0.781 and accuracy of 0.705. Radiomics-A0, with 10 features, had an AUC of 0.619 and accuracy of 0.523, while Radiomics-A1, with 8 features, had an AUC of 0.715 and accuracy of 0.591. The hybrid model exhibited better performance, with an AUC of 0.868 and accuracy of 0.875, than the radiological and Radiomics-Delta models, with an AUC of 0.759 and 0.781, respectively, and accuracy of 0.773 and 0.705, respectively.

CONCLUSION

Compared to Radiomics-A0 and Radiomics-A1, Radiomics-Delta demonstrated superior performance. Moreover, the hybrid model incorporating Radiomics-Delta and radiological features exhibited excellent performance in determining the LVI status in cases of invasive breast cancer.

Prediction of Receptor Status in Radiomics: Recent Advances in Breast Cancer Research

Breast cancer is a multifactorial heterogeneous disease and the leading cause of cancer-related deaths in women; its diagnosis and treatment require clinical sensitivity and a comprehensive disciplinary research approach. The expression of different receptors on tumor cells not only provides the basis for molecular typing of breast cancer but also has a decisive role in the diagnosis, treatment, and prognosis of breast cancer. To date, immunohistochemistry (IHC), which uses invasive histological sampling, has been extensively used in clinical practice to analyze the status of receptors and to make an accurate diagnosis of breast cancer. As an invasive assay, IHC can provide important biological information on tumors at a single point in time, but cannot predict future changes (due to treatment or tumor mutations) without additional invasive procedures. These issues highlight the need to develop a non-invasive method for predicting receptor status. The emerging field of radiomics may offer a non-invasive approach to identification of receptor status without requiring biopsy. In this paper, we present a review of the latest research results in radiomics for predicting the status of breast cancer receptors, with potential important clinical applications.